Global Blood Therapeutics (NASDAQ:GBT) Lowered to Equal Weight at Wells Fargo & Company
Global Blood Therapeutics (NASDAQ:GBT) Lowered to Equal Weight at Wells Fargo & Company
Wells Fargo & Company downgraded shares of Global Blood Therapeutics (NASDAQ:GBT – Get Rating) from an overweight rating to an equal weight rating in a report published on Tuesday, The Fly reports. The firm currently has $68.50 price target on the stock, up from their prior price target of $66.00.
據The Fly報道,在週二發佈的一份報告中,富國銀行將全球血液治療公司(納斯達克:GET-GET)的股票評級從增持下調至持平。該公司目前對該股的目標價為68.50美元,高於此前66.00美元的目標價。
A number of other research firms have also recently commented on GBT. Canaccord Genuity Group upgraded Global Blood Therapeutics from a hold rating to a buy rating and upped their price target for the stock from $40.00 to $72.00 in a research note on Monday. Stifel Nicolaus reiterated a hold rating on shares of Global Blood Therapeutics in a research note on Monday. JPMorgan Chase & Co. reduced their price objective on Global Blood Therapeutics from $39.00 to $36.00 and set a neutral rating on the stock in a research note on Tuesday, June 28th. William Blair cut Global Blood Therapeutics from an outperform rating to a market perform rating in a research note on Monday. Finally, Cowen cut Global Blood Therapeutics to a market perform rating and increased their price objective for the company from $67.00 to $68.50 in a research note on Tuesday. Nine research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Global Blood Therapeutics currently has an average rating of Hold and a consensus target price of $65.04.
其他一些研究公司最近也對GBT發表了評論。週一,Canaccel Genuity Group在一份研究報告中將全球血液治療公司的評級從持有評級上調為買入評級,並將該股目標價從40.00美元上調至72.00美元。Stifel Nicolaus在週一的一份研究報告中重申了對全球血液治療公司股票的持有評級。摩根大通在6月28日星期二的一份研究報告中將全球血液治療公司的目標價從39.00美元下調至36.00美元,並對該股設定了中性評級。威廉·布萊爾週一在一份研究報告中將全球血液治療公司的評級從表現優於市場下調至市場表現。最後,考恩在週二的一份研究報告中將全球血液治療公司下調至市場表現評級,並將該公司的目標價從67.00美元上調至68.50美元。9名研究分析師對該股的評級為持有,7名分析師對該股的評級為買入。根據MarketBeat的數據,全球血液治療公司目前的平均評級為持有,共識目標價為65.04美元。
Global Blood Therapeutics Stock Down 0.0 %
全球血液治療類股下跌0.0%
NASDAQ:GBT opened at $66.59 on Tuesday. The company has a quick ratio of 7.74, a current ratio of 8.52 and a debt-to-equity ratio of 4.34. The stock's fifty day moving average is $32.87 and its two-hundred day moving average is $31.36. Global Blood Therapeutics has a 52 week low of $21.65 and a 52 week high of $73.02. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of -13.67 and a beta of 0.83.
納斯達克:綠色壁壘週二開盤報66.59美元。該公司的速動比率為7.74,流動比率為8.52,債務權益比率為4.34。該股的50日移動均線切入位為32.87美元,200日移動均線切入位為31.36美元。全球血液治療公司的52周低點為21.65美元,52周高點為73.02美元。該股市值為43.3億美元,市盈率為-13.67倍,貝塔係數為0.83。
Insider Activity at Global Blood Therapeutics
全球血液治療公司的內部活動
In other Global Blood Therapeutics news, Director Philip A. Pizzo sold 1,260 shares of the firm's stock in a transaction dated Tuesday, June 21st. The stock was sold at an average price of $27.25, for a total transaction of $34,335.00. Following the transaction, the director now owns 9,112 shares of the company's stock, valued at $248,302. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.90% of the stock is currently owned by corporate insiders.
在全球血液治療公司的其他新聞中,董事菲利普·A·皮佐在一筆日期為6月21日(星期二)的交易中出售了1,260股該公司的股票。該股以27.25美元的平均價格出售,總成交金額為34,335.00美元。交易完成後,董事現在持有該公司9,112股股票,價值248,302美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站訪問。4.90%的股份目前由企業內部人士持有。
Hedge Funds Weigh In On Global Blood Therapeutics
對衝基金參與全球血液治療
A number of hedge funds and other institutional investors have recently made changes to their positions in GBT. Allspring Global Investments Holdings LLC purchased a new position in shares of Global Blood Therapeutics during the fourth quarter worth about $1,092,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Global Blood Therapeutics by 18.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 45,871 shares of the company's stock worth $1,343,000 after buying an additional 7,099 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Global Blood Therapeutics in the fourth quarter valued at about $332,000. DekaBank Deutsche Girozentrale lifted its position in Global Blood Therapeutics by 2.8% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 22,050 shares of the company's stock valued at $659,000 after purchasing an additional 600 shares during the period. Finally, Banque Pictet & Cie SA acquired a new stake in Global Blood Therapeutics in the fourth quarter valued at about $1,293,000.
一些對衝基金和其他機構投資者最近改變了他們在GBT的頭寸。AllSpring Global Investments Holdings LLC在第四季度購買了全球血液治療公司的新頭寸,價值約1,092,000美元。第四季度,蘇黎世廣東銀行持有的全球血液治療公司股票增加了18.3%。蘇黎世廣東銀行現在持有45,871股該公司股票,價值1,343,000美元,在上個季度又購買了7,099股。奧本海默公司在第四季度收購了全球血液治療公司的新股份,價值約33.2萬美元。德意志銀行第四季度將其在全球血液治療公司的地位提高了2.8%。DekaBank Deutsche Girozentrale在此期間又購買了600股,現在擁有22,050股該公司股票,價值65.9萬美元。最後,Banque Pictet&Cie SA在第四季度收購了全球血液治療公司的新股份,價值約1,293,000美元。
Global Blood Therapeutics Company Profile
全球血液治療公司簡介
(Get Rating)
(獲取評級)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
全球血液治療公司是一家生物製藥公司,致力於發現、開發和提供針對服務不足的鐮狀細胞疾病(SCD)患者羣體的治療方法。該公司提供Oxbryta片劑,這是一種治療SCD的口服藥物,每天一次。它還在第二階段對青少年和兒童SCD患者的臨牀試驗中評估了單劑和多劑Oxbryta的安全性和藥代動力學。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- CVS and Walgreens Show Why Investment Objectives Matter
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
- 免費獲取StockNews.com關於全球血液治療(GBT)的研究報告
- 3M、霍尼韋爾、通用電氣在季度報告後收購嗎?
- CVS和Walgreens展示為什麼投資目標很重要
- 索菲金融股票終於準備好為投資者買單了嗎?
- 這隻國防股票的基本面和技術面都看漲
- 美敦力和直覺外科公司準備實現大增長嗎?
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《全球血液治療日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對全球血液治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。